SIMCERE PHARMACEUTICAL GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.38 HKD | -0.37% |
|
+3.45% | -19.76% |
| Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
| Apr. 10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,011 | 3,031 | 3,958 | 2,255 | 1,772 | - | - |
| Enterprise Value (EV) 2 | 3,016 | 2,945 | 3,796 | 2,255 | 1,492 | 1,405 | 1,772 |
| P/E ratio | 26.9 x | 12.6 x | 28.5 x | 22.7 x | 12.8 x | 10 x | 8.51 x |
| Yield | 1.99% | 2.05% | 1.56% | - | 2.72% | 3.38% | 3.6% |
| Capitalization / Revenue | 4.37 x | 3.86 x | 4.3 x | 2.46 x | 1.72 x | 1.48 x | 1.27 x |
| EV / Revenue | 4.38 x | 3.75 x | 4.13 x | 2.46 x | 1.44 x | 1.17 x | 1.27 x |
| EV / EBITDA | 27.9 x | 11 x | 24 x | 17.2 x | 7.88 x | 5.97 x | 6.15 x |
| EV / FCF | - | -46.9 x | - | - | 14.4 x | 13.5 x | 14.1 x |
| FCF Yield | - | -2.13% | - | - | 6.95% | 7.43% | 7.11% |
| Price to Book | 3.4 x | 2.97 x | 3.83 x | - | 1.66 x | 1.48 x | 1.29 x |
| Nbr of stocks (in thousands) | 2,608,642 | 2,628,291 | 2,660,377 | 2,616,723 | 2,568,798 | - | - |
| Reference price 3 | 7.533 | 7.325 | 10.26 | 6.117 | 4.995 | 4.995 | 4.995 |
| Announcement Date | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1CNY in Million2USD in Million3CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 746.6 | 688.7 | 785.2 | 919.9 | 917.9 | 1,033 | 1,200 | 1,395 |
| EBITDA 1 | - | 108 | 267 | 158.1 | 131.1 | 189.3 | 235.2 | 288.2 |
| EBIT 1 | - | 74.08 | 178.1 | 125.6 | 98.87 | 139.9 | 188.1 | 251.6 |
| Operating Margin | - | 10.76% | 22.68% | 13.65% | 10.77% | 13.55% | 15.68% | 18.04% |
| Earnings before Tax (EBT) 1 | - | 123 | 220.1 | 129.3 | 102.8 | 143.5 | 192.5 | 244.4 |
| Net income 1 | 148.8 | 102.3 | 236.7 | 135.8 | 99.28 | 140.5 | 179.8 | 213.1 |
| Net margin | 19.93% | 14.85% | 30.14% | 14.76% | 10.82% | 13.61% | 14.98% | 15.28% |
| EPS 2 | - | 0.2800 | 0.5800 | 0.3600 | 0.2700 | 0.3888 | 0.4976 | 0.5867 |
| Free Cash Flow 1 | - | - | -62.76 | - | - | 103.7 | 104.5 | 126 |
| FCF margin | - | - | -7.99% | - | - | 10.04% | 8.7% | 9.04% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 54.8% | 44.41% | 43.74% |
| FCF Conversion (Net income) | - | - | - | - | - | 73.82% | 58.12% | 59.16% |
| Dividend per Share 2 | - | 0.1500 | 0.1500 | 0.1600 | - | 0.1358 | 0.1689 | 0.1800 |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales 1 | - | 448.4 |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 312.5 | - |
| Net margin | - | - |
| EPS | 0.8600 | - |
| Dividend per Share | - | - |
| Announcement Date | 8/21/23 | 3/20/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.55 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 86 | 162 | - | 280 | 367 | - |
| Leverage (Debt/EBITDA) | - | 0.0421 x | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62.8 | - | - | 104 | 104 | 126 |
| ROE (net income / shareholders' equity) | - | 19.7% | 25.7% | 13.8% | - | 12.4% | 14.7% | 16% |
| ROA (Net income/ Total Assets) | - | 7.56% | 14.3% | 8.91% | - | 8.39% | 10.1% | 11.1% |
| Assets 1 | - | 1,353 | 1,657 | 1,524 | - | 1,676 | 1,783 | 1,916 |
| Book Value Per Share 2 | - | 2.220 | 2.470 | 2.680 | - | 3.010 | 3.370 | 3.860 |
| Cash Flow per Share 2 | - | 0.0400 | -0.0800 | 0.5200 | - | 0.2400 | 0.3900 | - |
| Capex 1 | - | 54.4 | 32 | 49.9 | - | 84.7 | 82.5 | 97.3 |
| Capex / Sales | - | 7.9% | 4.07% | 5.43% | - | 8.2% | 6.87% | 6.97% |
| Announcement Date | 10/12/20 | 3/25/21 | 3/24/22 | 3/31/23 | 3/20/24 | - | - | - |
1USD in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.995
CNY
Average target price
7.984
CNY
Spread / Average Target
+59.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.76% | 1.77B | |
| +20.17% | 43.75B | |
| +27.47% | 22.06B | |
| +14.71% | 14.46B | |
| +13.17% | 13.62B | |
| +39.02% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B |
- Stock Market
- Equities
- 2096 Stock
- Financials Simcere Pharmaceutical Group Limited
